HomeCompareCRHCF vs JNJ

CRHCF vs JNJ: Dividend Comparison 2026

CRHCF yields 2.39% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRHCF wins by $1.43M in total portfolio value
10 years
CRHCF
CRHCF
● Live price
2.39%
Share price
$53.56
Annual div
$1.28
5Y div CAGR
70.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.46M
Annual income
$1,047,804.46
Full CRHCF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CRHCF vs JNJ

📍 CRHCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRHCFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRHCF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRHCF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRHCF
Annual income on $10K today (after 15% tax)
$203.13/yr
After 10yr DRIP, annual income (after tax)
$890,633.79/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CRHCF beats the other by $886,647.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRHCF + JNJ for your $10,000?

CRHCF: 50%JNJ: 50%
100% JNJ50/50100% CRHCF
Portfolio after 10yr
$743.1K
Annual income
$526,246.93/yr
Blended yield
70.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CRHCF
Analyst Ratings
7
Buy
4
Hold
1
Sell
Consensus: Buy
Altman Z
3.0
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRHCF buys
0
JNJ buys
0
No recent congressional trades found for CRHCF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRHCFJNJ
Forward yield2.39%2.13%
Annual dividend / share$1.28$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR70.8%28%
Portfolio after 10y$1.46M$30.3K
Annual income after 10y$1,047,804.46$4,689.40
Total dividends collected$1.40M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CRHCF vs JNJ ($10,000, DRIP)

YearCRHCF PortfolioCRHCF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,108$408.17$10,592$272.30+$516.00CRHCF
2$12,609$723.75$11,289$357.73+$1.3KCRHCF
3$14,804$1,311.43$12,123$472.89+$2.7KCRHCF
4$18,297$2,457.65$13,141$629.86+$5.2KCRHCF
5$24,427$4,848.96$14,408$846.81+$10.0KCRHCF
6$36,470$10,333.24$16,021$1,151.60+$20.4KCRHCF
7$63,650$24,626.72$18,122$1,588.22+$45.5KCRHCF
8$136,713$68,607.03$20,930$2,228.20+$115.8KCRHCF
9$381,507$235,224.40$24,792$3,191.91+$356.7KCRHCF
10$1,456,017$1,047,804.46$30,274$4,689.40+$1.43MCRHCF

CRHCF vs JNJ: Complete Analysis 2026

CRHCFStock

CRH plc, through its subsidiaries, manufactures and distributes building materials. It operates in three segments: Americas Materials, Europe Materials, and Building Products. The company manufactures and supplies cement, lime, aggregates, precast, ready mixed concrete, and asphalt products; concrete masonry and hardscape products comprising pavers, blocks and kerbs, retaining walls, and related patio products; and glass and glazing products, including architectural glass, custom-engineered curtain and window walls, architectural windows, storefront systems, doors, skylights, and architectural hardware. It also offers precast concrete and polymer-based products, such as underground vaults, drainage pipes and structures, utility enclosures, and modular precast structures to the water, energy, communication, transportation, and building structures markets; and construction accessories, such as anchoring, fixing, and connection solutions, as well as lifting systems, formwork accessories, and other accessories used in construction applications. In addition, the company offers network access products, which include composite access chambers, covers, passive safety systems, retention sockets, sealants, and meter boxes; and paving and construction services. Further, it provides building and civil engineering contracting, contract surfacing, operates logistics and owned railway infrastructure; sells and distributes cement; and supplies access chambers and ducting products. It serves governments, contractors, homebuilders, homeowners, and sub-contractors. The company operates primarily in the Republic of Ireland, the United Kingdom, the rest of Europe, the United States, and internationally. CRH plc was founded in 1936 and is headquartered in Dublin, Ireland.

Full CRHCF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CRHCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRHCF vs SCHDCRHCF vs JEPICRHCF vs OCRHCF vs KOCRHCF vs MAINCRHCF vs ABBVCRHCF vs MRKCRHCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.